1[1]Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ, 1994, 308:81
2[2]Hart RG, Halperin JL. Atrial fibrillation and stroke: revisiting the dilemmas. Stroke, 1994, 25:1337
3[3]Goldschmidt-Clermont PJ, Schulman SP, Bray PF, et al. Refining the treatment of women with unstable angina-a randomized, double-blind, comparative safety and efficacy evaluation of integrelin versus aspirin in the management of unstable angina. Clin Cardiol, 1996, 19:869
4[4]Fornaro G, Rossi P, Mantica P, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. Circulation, 1991, 87:162
5[5]Rajah SM, Nair U, Rees M, et al. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg, 1994, 107:1146
6[6]Murray JC, Kelly MA, Gorelick PB. Ticlopidine: a new antiplatlet agent for the secondary prevention of stroke. Clin Neurophamacol, 1994, 17:23
7[7]Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation, 1990:82
8[8]Colombo A, Hall P, Nakamula S, et al. Introcolonary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation, 1995, 91:1676
9[9]CAPRIE. Steering Committee. A randomized, blind, trial of clopidogrel versus aspirin in patients at risk of isochemic events (CAPRIE)
10[10]Hoet B, Falcon C, De Reys S, et al. R 68070, a combined thromboxane endoperoxide receptor antagonist and thromboxane synthase inhibitor, in human platelet activation in vitro and in vivo: a comparison with aspirin. Blood, 1990, 75:646
